The Carlyle Group made a strategic growth investment and will acquire a majority stake in TriNetX, a global health research network focused on clinical research to bring new therapies to market faster.
Terms of the deal were undisclosed.
The $221 billion private equity giant has invested more than $15 billion of equity since inception in healthcare-oriented companies.
“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities,” said Joe Bress, a principal specializing in healthcare at The Carlyle . . .
Continue Reading With Our Special Offer
Unlock this article instantly, along with the rest of our premium content and newsletters, with a 20% discount by using the coupon code VIDRIO2021.
Already a subscriber? Log in.